.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED02_Ceritinib.Ceritinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED02_Ceritinib.Ceritinib| name: | Ceritinib |
| ATC code: | L01ED02 | route: | oral |
| n-compartments | 2 |
Ceritinib is an oral, selective anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). It is approved for adults and is generally considered after failure of or intolerance to crizotinib.
Pharmacokinetic parameters in adult cancer patients (NSCLC), majority male, aged typically between 22–78 years, with normal hepatic and renal function.
Hong, Y, et al., & Lau, YY (2017). Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase. Journal of clinical pharmacology 57(5) 652–662. DOI:10.1002/jcph.849 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27922734
Deeks, ED (2016). Ceritinib: a Review in ALK-Positive Advanced NSCLC. Targeted oncology 11(5) 693–700. DOI:10.1007/s11523-016-0460-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27699584